Disease · MONDO_0001583

diabetic polyneuropathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diabetic polyneuropathy. Diseases, record MONDO_0001583. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001583

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diabetic polyneuropathy; Open Targets
Open Targets ID: MONDO_0001583; Open Targets
Other names: polyneuropathy in diabetes; Open Targets
Disease Ontology: DOID:12785; Disease Ontology
Highest stage of its drugs: Phase 3, for 8 of its 23 drugs, from ClinicalTrials.gov; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LIPOIC ACID, ALPHA	CHEMBL33864	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BENFOTIAMINE	CHEMBL4303665	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
INOSINE	CHEMBL1556	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NIACINAMIDE	CHEMBL1140	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREGABALIN	CHEMBL1059	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RIBOFLAVIN	CHEMBL1534	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SUCCINIC ACID	CHEMBL576	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CEBRANOPADOL	CHEMBL2364605	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ROSUVASTATIN	CHEMBL1496	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets46

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CACNA1A	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1C	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1E	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/777	Drugs and targets
CACNA1F	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1G	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/8913	Drugs and targets
CACNA1H	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/8912	Drugs and targets
CACNA1I	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/8911	Drugs and targets
CACNA1S	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/779	Drugs and targets

1 to 10 of 46

See all 46 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01201317	A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy	Phase 2	134	2013-09-25	Neuropathic Pain	AZD2423	Its record names the disease	ClinicalTrials.gov
NCT01313117	Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy	Phase 1/2	9	2014-10-02	Peripheral Neuropathy	LIPOIC ACID, ALPHA	Its record names the disease	ClinicalTrials.gov
NCT00977483	Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)	Phase 3	460		Diabetic Polyneuropathy	LIPOIC ACID, ALPHA	Its record names the disease	ClinicalTrials.gov
NCT00414349	Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain	Phase 3	431		Neuropathic Pain	LIDOCAINE, PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00307749	Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy	Phase 2	420		Diabetic Polyneuropathy	COLENEURAMIDE	Its record names the disease	ClinicalTrials.gov
NCT04649203	Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy	Phase 3	216		Diabetic Neuropathies	INOSINE, NIACINAMIDE, RIBOFLAVIN, SUCCINIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00508430	ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy	Phase 2	199		Diabetic Neuropathies	GABAPENTIN ENACARBIL	Its record names the disease	ClinicalTrials.gov
NCT01347671	Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy	Phase 2	189		Pain, Diabetic Neuropathies	CEBRANOPADOL	Its record names the disease	ClinicalTrials.gov
NCT00328601	Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)	Phase 3	170		Diabetic Polyneuropathy	LIPOIC ACID, ALPHA	Its record names the disease	ClinicalTrials.gov
NCT00878293	Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic	Phase 2	90		Diabetic Polyneuropathy	CEBRANOPADOL, MORPHINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35680173	RESULT	1	PubMed
19485723	RESULT	1	PubMed
19480610	RESULT	1	PubMed
19301937	RESULT	1	PubMed
26290682	DERIVED	1	PubMed
21775755	DERIVED	1	PubMed
17065669	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001583

GET https://conductscience.org/api/diseases/v1/MONDO_0001583/drugs?page=2

API reference For AI assistants